Table 1

Characteristics of included studies

StudyCriteria definite neurosyphilisCriteria probable neurosyphilisCases definite neurosyphilisCases probable neurosyphilisCases without neurosyphilisPCR targetSensitivity definite neurosyphilisSpecificity definite neurosyphilisSensitivity probable neurosyphilisSpecificity probable neurosyphilis
Castro et al 17 CSF TPHA/FTA-ABS and WCC>10 OR CSF VDRL/RPRN/A33N/A91tp4775.80%86.80%
polA69.70%92.30%
Dumareq et al 20 CSF VDRLCSF WCC count of >20 cells/mL with a non-reactive CSF VDRL191192tp47 and polA and bmp40%61%89%67%
Molepo et al 19 CSF VDRL and FTA-ABSN/A35N/A15tp4765%66%
GarcĂ­a et al 24 VDRL OR MH-TPAN/A8N/A25tp4750%100%
Moskophidis et al 23 CSF pleocytosis and raised CSF-protein and raided CSF-IgGN/A10N/A0tp4760%
Marra et al 33 CSF VDRLN/A2N/A79tp47100%100%
  • CSF, cerebrospinal fluid; FTA-ABS, fluorescent treponemal antibody-adsorption; MH-TPA, micro haema-agglutination Treponema pallidum assay; RPR, rapid plasma reagin; TPHA, Treponema pallidum haem-agglutination assay; VDRL, Venereal Disease Research Laboratory; WCC, white cell count.